About this episode
In this episode, Valentin Fuster reviews the September 17, 2024, JACC issue, highlighting pivotal studies on metabolic surgery's impact on cardiovascular risk in obstructive sleep apnea patients, and the potential of DPP-4 inhibitors in aortic valve calcification. He also discusses the benefits of Sitagliptin for heart failure and the prognostic value of plasma immunoglobulins in pulmonary arterial hypertension, closing with a look at genotype-guided antiplatelet therapy.
Get every episode summarized
Each time JACC This Week publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from JACC This Week
March 10, 2026: Inside JACC Stats: The State of CV Health in Focus | JACC this W...
JACC This Week
March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inh...
JACC This Week
February 24, 2026: ACHD Guideline in Focus—From Survival to Stewardship | JACC T...
JACC This Week
February 17, 2026: Women's Cardiovascular Health in Focus: From Inclusion to Red...
JACC This Week